5 results about "Corneal epithelial cell" patented technology

This invention discloses the application of low-concentration topical anesthetics in ophthalmic surgery, relating to the field of low-concentration topical anesthetic application technology, including the following specific application process: confirming the patient's basic surgical condition before administration; selecting anesthetic drugs and optimizing the administration concentration; performing administration according to the specific situation; real-time dynamic monitoring and adjustment of the administration dosage; gradually reducing the drug and transitioning to withdrawal. This invention improves drug safety and patient compliance while ensuring analgesic effects by optimizing anesthetic drug concentration and administration method. Furthermore, by using topical anesthetics at concentrations lower than conventional anesthetics for local administration after ophthalmic surgery, it can effectively relieve postoperative pain, discomfort, and foreign body sensation while significantly reducing toxic effects on corneal epithelial cells, reducing delayed corneal healing, dry eye, and corneal damage. It is effectively applicable to analgesia management after pterygium excision, refractive surgery, and other common ophthalmic surgeries, and has good clinical application value.

The present invention relates to use of a recombinant type III humanized collagen and a composition comprising the same in an eye. Provided are use of a recombinant type III humanized collagen in the preparation of a product for preventing and / or treating eye inflammation, a composition comprising the recombinant type III humanized collagen, and use of the composition in the preparation of a product for preventing and / or treating eye inflammation and / or eye dryness. The recombinant type III humanized collagen and the composition comprising the same can significantly promote the renewal and repair of corneal epithelial cells, and can also inhibit the release of inflammatory mediators, enhancing the ocular tissue barrier, enhancing tear film stability, and alleviating eye inflammation and eye dryness.

This invention discloses the application of necrotizing 1 (Necrostatin-1) in the preparation of drugs for the prevention and / or treatment of dry eye, relating to the field of biomedical technology. The application of necrotizing 1 in the preparation of drugs for the prevention and / or treatment of dry eye is described. This invention is the first to discover the application of the programmed necrosis inhibitor Necrostatin-1 in the treatment of dry eye. Nec-1, by inhibiting programmed necrosis, can effectively protect corneal epithelial cells and reduce ocular surface inflammation and damage. In a scopolamine-induced dry eye model, subconjunctival injection of 0.3 μM Nec-1 significantly improved dry eye symptoms, including reduced corneal defects and increased tear secretion, without significant drug toxicity. Nec-1 provides a new targeting strategy for dry eye treatment and may become a potent and effective drug for the clinical treatment of dry eye in the future.

This invention relates to a method for inducing corneal epithelial cells from the differentiation of pluripotent stem cells. More specifically, it relates to a method for autonomously differentiating pluripotent stem cells, such as human iPS cells, into ectodermal cell lines in a serum-free culture medium without the use of feeder cells, and then inducing the resulting ocular surface ectodermal cell lines to differentiate into corneal epithelial cells.

The application relates to the technical field of eye nanometer preparation, and discloses a cell membrane-coated glycyrrhizinic acid nanometer eye drop, a preparation method and application thereof. The eye drop comprises cell membrane-coated glycyrrhizinic acid nanoparticles and an eye-acceptable medium; the nanoparticles are composed of a nanometer core containing glycyrrhizinic acid or a pharmaceutically acceptable salt thereof and a cell membrane layer coated on the outside of the nanometer core; and the cell membrane is derived from corneal epithelial cells, conjunctival epithelial cells, macrophages, red blood cells or mixed membranes thereof. In the preparation, glycyrrhizinic acid nanometer cores and cell membrane vesicles are obtained respectively, and then the permeability, pH and viscosity are adjusted after ultrasonic treatment, extrusion or microfluidic fusion, and sterile filling is carried out. The preparation has the characteristics of nanometer dispersion, biomimetic coating and ocular surface retention, and can be used for preparing eye drugs for ocular surface inflammation, corneal epithelial injury or dry eye related diseases.